A European perspective on immunotherapy for food allergies
- 作者：Kirsten Beyer ; MD ; kirsten.beyer@charite.de
- 关键词：Allergy ; food ; immunotherapy ; oral ; sublingual ; modified allergens ; native allergens ; European Medicine Agency
- 刊名：Journal of Allergy and Clinical Immunology
- 出版年：2012
- 期刊代码：158_00916749
- 类别：med
- 出版时间：May, 2012
- 卷：129
- 期：5
- 页码：1179-1184
- 文件大小：109 K
摘要
Food allergies are common, and frequently, the only treatment option is strict avoidance. Unfortunately, many patients accidentally ingest allergenic foods, which can result in severe anaphylactic reactions. Several immunotherapies are being developed for food allergies; these involve oral, sublingual, epicutaneous, or subcutaneous administration of small amounts of native or modified allergens to induce immune tolerance. Oral immunotherapy seems to be the most promising approach based on results from small uncontrolled and controlled studies. However, it is a challenge to compare results among immunotherapy trials because of differences in protocols. Studies conducted thus far have tested the most prevalent food allergens: it is not clear whether their results can be extended to other allergens. Sublingual administration of immunotherapy has shown some efficacy and fewer side effects than oral administration in some trials, yet neither approach can be recommended for routine practice. Controlled studies with larger numbers of subjects are needed to determine short- and long-term efficacy and side effects. In Europe immunotherapy trials for food allergies face many ethical and regulatory issues. Guidelines from the European Medicine Agency on the clinical development of products for specific immunotherapy of allergic diseases do not adequately address immunotherapy for food allergies, especially for therapies that orally administer native food or that include pediatric patients.